Current Issues of Pharmacy and Medical Sciences

Elaboration and validation of a new capillary electrophoresis (CE) method in non-aqueous milieu for the analysis of ...

Annales UMCS, Sectio DDD, Pharmacia, Vol. XXIX, N 4, 1

ANNA BERECKA, ANNA GUMIENICZEK, ŁUKASZ KOMSTA,
TADEUSZ INGLOT, PATRYCJA MROCZKA

Department of Medicinal Chemistry, Faculty of Pharmacy, Medical University of Lublin, Poland

Abstract

Elaboration and validation of a new capillary electrophoresis (CE) method in non-aqueous milieu for the analysis of hypoglycemic drug repaglinide in pharmaceuticals

 

Capillary electrophoresis (CE) method in non-aqueous medium was developed and validated for determination of repaglinide in pharmaceutical formulation. CE was performed using a 75 µm x 90 cm fused silica capillary (76 cm effective length) and UV detection at 240 nm. 0.01 mol/l solution of ammonium acetate in the mixture of methanol-acetonitrile (3:7, v/v), 30 kV voltage, 30°C temperature and hydrodynamic injection (10 mbar, 6 s) were chosen as CE parameters. The solutions were prepared in methanol. The proposed CE method demonstrated sufficient stability and reproducibility with mean RSD values of less than 2.5%. The robustness, selectivity, linearity, accuracy and precision were sufficient for quantitative determination of repaglinide for different pharmaceutical purposes.

Files to download

Keywords

capillary electrophoresis, validation, repaglinide, pharmaceuticals

References

  1. Berecka A., Gumieniczek A., Hopkała H.: Development and validation of a new high-performance liquid chromatography method for the determination of gliclazide and repaglinide in pharmaceutical formulations. J. AOAC Int. 89, 319, 2006.
  2. Maier V., Znaleziona J., Jirovský D., Skopalová J., Petr J., Śevčik J.: Determination of anti-hyperglycemic drugs in nanomolar concentration levels by micellar electrokinetics chromatography with non-ionic surfactant. J. Chromatogr. A 1216, 4492, 2009.
  3. Mandić Z., Gabelica V.: Ionization, lipophilicity and solubility properties of repaglinide. J. Pharm. Biomed. Anal. 32, 866, 2006.
  4. Reddy K.V.S.R.K., Babu M., Mathad V.T., Eswaraiach S., Reddy M.S., Dubey P.K., Vyas K.: Impurity profile study of repaglinide. J. Pharm. Biomed. Anal. 32, 461, 2003.
  5. Ruzilawati A.B., Wahab M.S.A., Imran A., Ismail Z., Gan S.H.: Method development and validation of repaglinide in human plasma by HPLC and its application in pharmacokinetic studies. J. Pharm. Biomed. Anal. 43, 1831, 2007.
  6. Wang M., Miksa I.R.: Multi-component plasma quantitation of anti-hyperglycemic pharmaceutical compounds using liquid chromatography-tandem mass spectrometry. J. Chromatogr. B–Biomed. Appl. 856, 318, 2007.
  7. Yao J., Shi Y-Q., Li Z-R., Jin S-H.: Development of a RP-HPLC method for screening potentially countering anti-diabetic drugs. J. Chromatogr B 853, 254, 2007.
  8. European Pharmacopoeia 6th edn. Council of Europe, Strasbourg, France, 2007. Anna Berecka, Anna Gumieniczek, Łukasz Komsta, Tadeusz Inglot, Patrycja Mroczka

Calendar

March 2021

Mon Tue Wed Thu Fri Sat Sun
01 02 03 04 05 06 07
08 09 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30 31